Jonathan Lim, MD, Chairman and CEO of Ignyta, Inc. gives an overview of his clinical trial, STARTRK-2 and the use of entrectinib, an investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors, at the 2017 ASCO Annual Meeting in Chicago, IL.
STARTRK-2: A Phase II Study on Use of Entrectinib in NTRK1/2/3, ROS1, or ALK Gene Fusions
